4'-hydroxy-[1,1'-biphenyl]-4-carbohydrazide | 849421-25-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4'-hydroxy-[1,1'-biphenyl]-4-carbohydrazide
• 英文别名: 4-(4-hydroxyphenyl)benzohydrazide
• CAS: 849421-25-6
• 化学式: C₁₃H₁₂N₂O₂
• mdl: MFCD12031990
• 分子量: 228.25
• InChiKey: DGBZEJPSTNFCPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  75.4
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4'-hydroxy-[1,1'-biphenyl]-4-carbohydrazide 在 potassium hydroxide 作用下， 以 乙醇 为溶剂， 反应 2.58h， 生成 1-(4-chlorophenyl)-2-((5-(4'-hydroxy-[1,1'-biphenyl]-4-yl)-1,3,4-oxadiazol-2-yl)thio)ethan-1-one
  参考文献：
  名称：

  靶向 EGFR 变构位点的 4'-羟基-[1,1'-联苯]-4-碳酰肼席夫碱和恶二唑衍生物的体外和计算机评估

  摘要：

  抑制 EGFR 酪氨酸激酶 (TK) 活性被认为是一种有前途的癌症治疗策略。 I 型和 II 型 EGFR TK 抑制剂结合 ATP 结合位点，而 III 型和 IV 型抑制剂则针对各种激酶中存在的靠近 ATP 结合位点的变构敏感袋。目前的工作旨在合成新的含联苯衍生物，根据分子对接研究，这些衍生物预计可作为 EGFR 酪氨酸激酶变构位点抑制剂。合成了一系列新型 4'-羟基-[1,1'-联苯]-4-碳酰肼衍生物 ( W3–W15 )，并使用红外、 1 HNMR、 13 CNMR 光谱和高分辨率质谱进行表征。化合物W4具有良好的药效团拟合评分，表明其可能具有与参考 6DUK（结合有变构抑制剂的 EGFR）相似的生物活性。化合物W4对 EGFR TK 变构位点表现出良好的 ΔG 评分，表明化合物-受体复合物形成的可能性很高，并且预计它不会致癌且无刺激性。与所研究的其他两种细胞系（HCT-116 结直肠癌细胞和

  DOI：

  10.1007/s11696-024-03648-3
• 作为产物：
  描述：

  4-羟基-4-联苯基羧酸乙酯 在 一水合肼 作用下， 反应 8.0h， 生成 4'-hydroxy-[1,1'-biphenyl]-4-carbohydrazide
  参考文献：
  名称：

  Discovering Potent Inhibitors Against the β-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) of Helicobacter pylori: Structure-Based Design, Synthesis, Bioassay, and Crystal Structure Determination

  摘要：

  The discovery of HpFabZ inhibitors is now of special interest in the treatment of various gastric diseases. In this work, three series of derivatives (compounds 3, 4, and 5) were designed, synthesized, and their biological activities were investigated as potential HpFabZ inhibitors in a two phased manner. First, we designed and synthesized two series of derivatives (3a-r and 4a-u) and evaluated the enzyme-based assay against HpFabZ. Five compounds (3i-k, 3m, and 3q) showed potential inhibitory activity, with IC(50) values less than 2 muM. Second, a focused combinatorial library containing 280 molecules was designed employing the LD1.0 program. Twelve compounds (5a-l) were selected and synthesized. The activity of the most potent compound 5h (IC(50) = 0.86 muM) was 46 times higher than that of the hit 1. The high hit rate and the potency of the new HpFabZ inhibitors demonstrated the efficiency of the strategy for the focused library design and virtual screening.

  DOI：

  10.1021/jm8015602

文献信息

• POLYACETAL RESIN COMPOSITION
  申请人：Polyplastics Co., Ltd.

  公开号：EP1679346A1

  公开（公告）日：2006-07-12

  A polyacetal resin composition comprises a polyacetal resin, and a polycyclic aromatic carboxylic acid hydrazide or a polycyclic aromatic carboxylic acid hydrazide having a substituent. The proportion of the polycyclic aromatic carboxylic acid hydrazide may be about 0.001 to 20 parts by weight relative to 100 parts by weight of the polyacetal resin. The polyacetal resin composition may further comprise at least one member selected from an antioxidant, a heat stabilizer, a processing stabilizer, a weather (light)-resistant stabilizer, an impact resistance improver, a slip-improving agent, a coloring agent, and a filler. With the use of such a resin composition, stability of a polyacetal resin is improved, and formaldehyde emission is inhibited.

  聚缩醛树脂组合物由聚缩醛树脂、多环芳香族羧酸酰肼或具有取代基的多环芳香族羧酸酰肼组成。相对于 100 重量份的聚缩醛树脂，多环芳香族羧酸酰肼的比例约为 0.001 至 20 重量份。聚缩醛树脂组合物可进一步包含至少一种选自抗氧化剂、热稳定剂、加工稳定剂、耐候（光）稳定剂、抗冲击性改进剂、滑爽性改进剂、着色剂和填料的成分。使用这种树脂组合物可以提高聚缩醛树脂的稳定性，并抑制甲醛释放。
• 10.2174/0109298673305163240427065543
  作者：Shihab, Wurood A.、Razzak Kubba, Ammar A.、Tahtamouni, Lubna H.、Saleh, Khaled M.、Alsakhen, Mai F.、Kanaan, Sana I.、Saleh, Abdulrahman M.、Yasin, Salem R.

  DOI：10.2174/0109298673305163240427065543

  日期：——

  inhibitors. The current work aimed to synthesize new biphenyl-containing derivatives that were predicted to act as EGFR TK allosteric site inhibitors based on molecular docking studies. Method: A new series of 4'-hydroxybiphenyl-4-carboxylic acid derivatives, including hydrazine-1-carbothioamide (S3-S6) and 1,2,4-triazole (S7-S10) derivatives, were synthesized and characterized using IR, 1HNMR, 13CNMR, and

  简介：EGFR 酪氨酸激酶 （TK） 的变构抑制是目前设计和开发抗癌药物以避免临床批准的 ATP 竞争性抑制剂表现出化疗耐药性的最具吸引力的方法之一。目前的工作旨在合成新的含联苯衍生物，这些衍生物根据分子对接研究预测可作为 EGFR TK 变构位点抑制剂。方法： 合成一系列新的4'-羟基联苯-4-羧酸衍生物，包括肼-1-胡萝卜酰胺（S3-S6）和1,2,4-三唑（S7-S10）衍生物，并采用红外、1HNMR、13CNMR和HR-质谱对衍生物进行表征。化合物 S4 具有相对较高的药效团拟合评分，表明它可能具有与 EGFR 变构抑制剂参考相似的生物活性，并且它对 EGFR TK 变构位点的 ΔG 评分相对较低，表明药物受体复合物形成的可能性很高。化合物 S4 对测试的三种癌细胞系，特别是 HCT-116 结直肠癌细胞具有细胞毒性，IC50 值与厄洛替尼相当。化合物 S4 通过将 HCT-116
• Polyacetal resin composition
  申请人：Harashina Hatsuhiko

  公开号：US20070123617A1

  公开（公告）日：2007-05-31

  A polyacetal resin composition comprises a polyacetal resin, and a polycyclic aromatic carboxylic acid hydrazide or a polycyclic aromatic carboxylic acid hydrazide having a substituent. The proportion of the polycyclic aromatic carboxylic acid hydrazide may be about 0.001 to 20 parts by weight relative to 100 parts by weight of the polyacetal resin. The polyacetal resin composition may further comprise at least one member selected from an antioxidant, a heat stabilizer, a processing stabilizer, a weather (light)-resistant stabilizer, an impact resistance improver, a slip-improving agent, a coloring agent, and a filler. With the use of such a resin composition, stability of a polyacetal resin is improved, and formaldehyde emission is inhibited.
• Discovering Potent Inhibitors Against the β-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) of <i>Helicobacter pylori</i>: Structure-Based Design, Synthesis, Bioassay, and Crystal Structure Determination
  作者：Lingyan He、Liang Zhang、Xiaofeng Liu、Xianghua Li、Mingyue Zheng、Honglin Li、Kunqian Yu、Kaixian Chen、Xu Shen、Hualiang Jiang、Hong Liu

  DOI：10.1021/jm8015602

  日期：2009.4.23

  The discovery of HpFabZ inhibitors is now of special interest in the treatment of various gastric diseases. In this work, three series of derivatives (compounds 3, 4, and 5) were designed, synthesized, and their biological activities were investigated as potential HpFabZ inhibitors in a two phased manner. First, we designed and synthesized two series of derivatives (3a-r and 4a-u) and evaluated the enzyme-based assay against HpFabZ. Five compounds (3i-k, 3m, and 3q) showed potential inhibitory activity, with IC(50) values less than 2 muM. Second, a focused combinatorial library containing 280 molecules was designed employing the LD1.0 program. Twelve compounds (5a-l) were selected and synthesized. The activity of the most potent compound 5h (IC(50) = 0.86 muM) was 46 times higher than that of the hit 1. The high hit rate and the potency of the new HpFabZ inhibitors demonstrated the efficiency of the strategy for the focused library design and virtual screening.
• 10.1007/s11696-024-03648-3
  作者：Shihab, Wurood A.、Mahmood, Ammar A. Razzak、Tahtamouni, Lubna H.、AlSakhen, Mai F.、Kanaan, Sana I.、Saleh, Khaled M.、Yasin, Salem R.

  DOI：10.1007/s11696-024-03648-3

  日期：——

  (TK) activity is considered a promising therapeutic strategy for cancer treatment. Type I and II EGFR TK inhibitors bind the ATP-binding site, while type III and IV inhibitors target an allosterically sensitive pocket proximal to the ATP-binding site present in a variety of kinases. The current work aimed to synthesize new biphenyl-containing derivatives that were predicted to act as EGFR tyrosine kinase

  抑制 EGFR 酪氨酸激酶 (TK) 活性被认为是一种有前途的癌症治疗策略。 I 型和 II 型 EGFR TK 抑制剂结合 ATP 结合位点，而 III 型和 IV 型抑制剂则针对各种激酶中存在的靠近 ATP 结合位点的变构敏感袋。目前的工作旨在合成新的含联苯衍生物，根据分子对接研究，这些衍生物预计可作为 EGFR 酪氨酸激酶变构位点抑制剂。合成了一系列新型 4'-羟基-[1,1'-联苯]-4-碳酰肼衍生物 ( W3–W15 )，并使用红外、 1 HNMR、 13 CNMR 光谱和高分辨率质谱进行表征。化合物W4具有良好的药效团拟合评分，表明其可能具有与参考 6DUK（结合有变构抑制剂的 EGFR）相似的生物活性。化合物W4对 EGFR TK 变构位点表现出良好的 ΔG 评分，表明化合物-受体复合物形成的可能性很高，并且预计它不会致癌且无刺激性。与所研究的其他两种细胞系（HCT-116 结直肠癌细胞和